Background illustration for clinical trials search

Paid Clinical Trials Louisville

Discover 495 paid clinical trials in Louisville, Kentucky. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting

for
Pneumonia
Location: Louisville KY, Akron OH, Cleveland OH, Beachwood OH,
Sponsor: Pfizer

Sex: All

Age: 65+

Code: NCT05452941

Recruiting

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

for
Type 2 Diabetes
Location: Louisville KY, Cincinnati OH, Indianapolis IN,
Sponsor: Eli Lilly and Company

Sex: All

Age: 10 - 17

Code: NCT06739122

Phase3, Recruiting

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

for
HER2-negative Breast Cancer
Location: Louisville KY, Dayton OH, Portsmouth OH, Columbus OH,
Sponsor: NSABP Foundation Inc

Sex: Female

Age: 18+

Code: NCT03412643

Phase2, Recruiting

Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

for
Metastatic Breast Cancer
Location: Louisville KY
Sponsor: University of Louisville

Sex: Female

Age: 18+

Code: NCT04990921

Phase2, Recruiting

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for
Breast Cancer
Location: Louisville KY, Fairfield OH, Centerville OH,
Sponsor: Stemline Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06492616

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

for
Myelodysplastic Syndrome
Location: Louisville KY, Mattoon IL, Effingham IL, Danville IL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06577441

Phase2, Recruiting

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

for
Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer,
Location: Louisville KY, Pittsburgh PA, New York NY, Orlando FL,
Sponsor: Obsidian Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06060613

Phase1, Phase2, Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

for
Advanced Solid Tumors Cancer, MSI-H Cancer
Location: Louisville KY, Maumee OH, Chicago IL, Greenville SC,
Sponsor: Nimbus Wadjet, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06898450

Phase1, Phase2, Recruiting

Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma

for
Glioblastoma
Location: Louisville KY
Sponsor: University of Louisville

Sex: All

Age: 18+

Code: NCT05700955

Phase1, Recruiting

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

for
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma,
Location: Louisville KY, Cincinnati OH, Indianapolis IN,
Sponsor: Lyell Immunopharma, Inc.

Sex: All

Age: 18+

Code: NCT05826535

Phase1, Phase2, Recruiting

Combination Therapy for Recurrent Ovarian Cancer

for
Recurrent Ovarian Cancer
Location: Louisville KY
Sponsor: Sham Sunder Kakar

Sex: Female

Age: 18+

Code: NCT05610735

Phase1, Phase2, Recruiting

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

for
Melanoma
Location: Louisville KY
Sponsor: University of Louisville

Sex: All

Age: 18+

Code: NCT01638676

Phase1, Phase2, Recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

for
Advanced Melanoma
Location: Louisville KY, Knoxville TN, Columbus OH, Chicago IL,
Sponsor: Replimune, Inc.

Sex: All

Age: 12+

Code: NCT06264180

Phase3, Recruiting

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

for
Astrocytoma, IDH-Mutant, Grade 3
Location: Louisville KY, Cincinnati OH, West Chester OH,
Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 12+

Code: NCT07215910

Phase3, Recruiting

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

for
Anaplastic Large Cell Lymphoma, ALK-Negative,
Location: Louisville KY, Indianapolis IN, Columbus OH, Dublin OH,
Sponsor: Eastern Cooperative Oncology Group

Sex: All

Age: 18 - 70+

Code: NCT06724237

Phase3, Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

for
Carcinoma, Non-Small-Cell Lung
Location: Louisville KY, Owensboro KY, Edgewood KY, Nashville TN,
Sponsor: Mirati Therapeutics Inc.

Sex: All

Age: 18+

Code: NCT06875310

Phase3, Recruiting

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

for
Acute Myeloid Leukemia
Location: Louisville KY, Crown Point IN, New Lenox IL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06672146

Phase2, Recruiting

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

for
Locally Advanced Urothelial Carcinoma,
Location: Louisville KY, Mattoon IL, Effingham IL, Danville IL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06524544

Phase3, Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

for
Breast Neoplasms
Location: Louisville KY, Nashville TN, Urbana IL, Decatur IL,
Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT07173751

Phase3, Recruiting

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Louisville KY, Cincinnati OH, West Chester OH,
Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT06876714

Phase3, Recruiting